JNJ Stock Analysis: Buy, Sell, or Hold?
JNJ - Johnson & Johnson
$227.25
-0.04 (-0.02%)
▼
HOLD
MODERATE Confidence
Last Updated: January 30, 2026
Earnings: Apr 14, 2026
Get Alerted When JNJ Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
2 traders called JNJ this week
33% bullish • 2 bearish
33% bullish • 2 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: JNJ is fairly valued with market pricing in 0.3% annual growth. Fine to hold or accumulate slowly on dips.
📊 HOLD: JNJ is fairly valued with market pricing in 0.3% annual growth. Fine to hold or accumulate slowly on dips.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$306.87
Based on 6.4% avg growth
INTRINSIC VALUE TODAY
$190.54
Trading above fair value
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 18.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: JNJ is currently trading at $227.25, which is considered extended relative to its 30-day fair value range of $205.78 to $221.40. The stock's valuation (Forward PE: 18.1) is in line with its historical norms (18.0). At these levels, the market is pricing in 0.3% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, JNJ is in a strong uptrend. The price is approaching resistance at $230.00. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: JNJ has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, JNJ is in a strong uptrend. The price is approaching resistance at $230.00. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: JNJ has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
EXTENDED
Fair Price Range
$205.78 -
$221.40
Company Quality Score
63/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
58.1%
Protect Your Profits
JNJ is technically overbought (RSI 77). Consider hedging now to protect against a potential pullback while keeping your upside.
View Profit Protection PlanAll Signals
- BEARISH: Price extended above range
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- NEUTRAL: Near Wall St target ($227.92)
- NEUTRAL: Market pricing in 0.3% annual earnings growth - fairly valued
Fair Price Analysis
30-Day Fair Range
$205.78 -
$221.40
Current vs Fair Value
EXTENDED
Support & Resistance Levels
Support Level
$210.50
Resistance Level
$230.00
Current Trend
Strong Uptrend
Fundamental Context
Forward P/E (Next Year Est.)
18.13
Wall Street Target
$227.92
(+0.3%)
Revenue Growth (YoY)
9.1%
Earnings Growth (YoY)
48.6%
Profit Margin
28.5%
Valuation Premium vs History
+0.3% premium
PE vs Historical
18.1 vs 18.0
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+0.3%
(market-implied from PE analysis)
1-Year Target
$227.97
(+0%)
2-Year Target
$228.66
(+1%)
3-Year Target
$229.34
(+1%)
3-Yr Target (if PE normalizes)
(PE: 18→18)
PE COMPRESSION
$227.74
(+0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 22.3, Growth: 8.7%)
$359.23
(+58%)
Base:
(SPY PE: 18.1, Growth: 8.7%)
$292.00
(+29%)
Bear:
(PE: 15.4, Growth: 8.7%)
$248.20
(+9%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (21x PE), but valuation improves significantly next year (18x PE) as earnings recover.
Trailing PE: 20.66 | Current EPS (TTM): $11.02
Bull Case
$285.02
(+25%)
Analyst growth 13.8%, PE expands to 22.7
Base Case
$259.11
(+14%)
Market implied 13.8%, PE stable at 20.7
Bear Case
$154.85
(-32%)
Severe decline -20.0%, PE contracts to 17.6
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Last updated: January 31, 2026 12:10 AM ET
Data refreshes hourly during market hours. Next update: 1:10 AM
Data refreshes hourly during market hours. Next update: 1:10 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is JNJ showing a specific setup today?
Insider Activity (6 Months)
1
Buys
4
Sells
Net
INSIDERS SELLING
Recent Transactions
Ro Khanna
BUY
2025-09-29
Val T. Hoyle
SELL
2025-09-23
Jennifer L Taubert
SELL
56471 shares
2025-09-04
Featured in Portfolios
JNJ is a key holding in these high-performance investment strategies.
Top Rated Drug Manufacturers - General Stocks
Top-rated stocks in Drug Manufacturers - General by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
LLY
Eli Lilly and Company |
STRONG BUY
29 analysts |
$1111 | 60 BUY |
|
GILD
Gilead Sciences Inc |
BUY
30 analysts |
$135 | 63 BUY |
|
AMGN
Amgen Inc |
HOLD
32 analysts |
$332 | 66 BUY |
|
ABBV
AbbVie Inc |
BUY
28 analysts |
$245 | 61 BUY |
|
BIIB
Biogen Inc |
HOLD
37 analysts |
$192 | 58 HOLD |
Advanced JNJ Option Strategies
Professional options setups generated by AI based on today's JNJ price and gamma walls.
